Agios Publishes 2024 Environmental, Social and Governance (ESG) Report
April 09 2024 - 7:00AM
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular
metabolism and PK activation pioneering therapies for rare
diseases, today announced the publication of its 2024
Environmental, Social and Governance Report, which provides
corporate sustainability disclosures for the period Jan. 1, 2023 to
Dec. 31, 2023.
“As we continue to drive meaningful advances in red blood cell
health for patients with rare diseases, ‘how’ we achieve our
mission is just as important as ‘what’ we accomplish. Our ESG
report is a shining reflection of our ‘how’ and a testament to the
important contributions made by every function at Agios,” said
Brian Goff, chief executive officer of Agios. “We firmly believe
that our success is not only tied to milestones or financial
performance, but is also intrinsically linked to doing what is
right for patients, the communities we serve and live in, and
society as a whole. I am grateful to our patients, employees,
partners and all our stakeholders who collaborate with us on our
shared journey to transform the landscape of rare diseases.”
Key highlights of the report include:
- Diversity in clinical trials: Robust efforts
to support diversity and inclusion in clinical trials is a strong
focus at Agios. From designing protocols to building trust among
diverse patient communities to supporting trial awareness efforts,
patients and caregivers continue to play a key role in Agios
clinical trials.
- Diversity in the life sciences industry:
Through community partnerships, supplier diversity efforts,
inclusive hiring practices and health equity collaborations, Agios
prioritizes equitable pathways within the biotech industry.
- Diversity at Agios: Representative, cognitive
and experiential differences among team members are highly valued
at Agios, and the company demonstrated tangible successes in 2023.
For example, the number of employee resource groups (ERGs) doubled.
There is strong female representation across all layers of the
organization, with 50% of the board, 63% of the C-suite, 56% of
senior management and 59% of the total employee population
identifying as female.
Agios’ ESG program is overseen by its board of directors. The
board receives updates on ESG and sustainability from the executive
leadership team, including Agios’ chief executive officer, chief
financial officer and chief people officer, as well as the leader
of the cross-functional ESG working group made up of individuals
representing the entire organization, including clinical
development, market access, human resources, legal, information
technology, facilities, technical operations and external
communications.
To learn more about ESG at Agios, read the full
report here.
About AgiosAgios is the pioneering leader in PK
activation and is dedicated to developing and delivering
transformative therapies for patients living with rare diseases. In
the U.S., Agios markets a first-in-class pyruvate kinase (PK)
activator for adults with PK deficiency, the first
disease-modifying therapy for this rare, lifelong, debilitating
hemolytic anemia. Building on the company's deep scientific
expertise in classical hematology and leadership in the field of
cellular metabolism and rare hematologic diseases, Agios is
advancing a robust clinical pipeline of investigational medicines
with programs in alpha- and beta-thalassemia, sickle cell disease,
pediatric PK deficiency, MDS-associated anemia and phenylketonuria
(PKU). In addition to its clinical pipeline, Agios is advancing a
preclinical TMPRSS6 siRNA as a potential treatment for polycythemia
vera. For more information, please visit the company’s website
at www.agios.com.
Contacts:
Investor ContactChris Taylor, VP, Investor
Relations and Corporate CommunicationsAgios
PharmaceuticalsIR@agios.com
Media ContactDan Budwick1ABdan@1abmedia.com
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Apr 2024 to May 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From May 2023 to May 2024